指南与共识血栓与止血

血友病A基因治疗valoctocogene roxaparvovec的肝脏相关方面:临床实践专家指导

Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice.
指南 / 共识 · Blood Adv · 2024-01-01

本文由血友病专家小组制定推荐,阐述血友病A基因治疗valoctocogene roxaparvovec前后肝功能监测。治疗前需评估肝脏状况以确定资格,禁忌包括未控制肝脏感染、自身免疫性肝炎、肝硬度≥8 kPa或肝硬化;治疗后第一年每周监测ALT 1-2次,发现≥1.5×ULN升高需免疫抑制治疗,并长期监测。

要点

  • 肝硬度≥8 kPa、肝硬化、未控制肝脏感染或自身免疫性肝炎患者禁用基因治疗。
  • 治疗前应进行实验室检查、腹部超声和瞬时弹性成像检测肝硬度。
  • 治疗后第一年每周监测ALT 1-2次,ALT升高时用泼尼松60 mg/d治疗。

核心结论

  • 选择肝脏健康良好的患者并密切监测,ALT升高可及时治疗并预计无长期肝脏后遗症。

研究设计与样本

  • 本文为血友病专家小组制定的专家指导推荐,基于专家共识提出基因治疗前后肝功能监测建议。

主要发现

  • 基因治疗禁用于未控制肝脏感染、自身免疫性肝炎、肝硬度≥8 kPa或肝硬化患者。
  • 肝酶异常包括丙氨酸氨基转移酶(ALT)任何水平高于正常上限(ULN)的患者不推荐治疗。
  • 治疗后第一年应每周监测ALT 1至2次以发现≥1.5×ULN的升高,可能需要免疫抑制治疗。
  • ALT升高患者应接受泼尼松60 mg/d治疗2周,ALT恢复基线后逐步减量。
  • ALT监测应长期持续(每3-6个月),同时每6个月腹部超声和每年瞬时弹性成像评估。

关键数值与推荐

  • 肝硬度≥8 kPa或肝硬化患者禁用基因治疗。
  • ALT任何水平高于ULN的患者不推荐治疗。
  • 治疗后第一年ALT监测频率为每周1至2次,以检测≥1.5×ULN的升高。
  • ALT升高时泼尼松60 mg/d用2周,ALT恢复基线后逐步减量。
  • 长期ALT监测每3-6个月,腹部超声每6个月,瞬时弹性成像每年。

临床怎么用

  • 治疗前评估肝脏健康应包括实验室检查、腹部超声和瞬时弹性成像肝硬度检测。
  • 治疗后第一年密切监测ALT以及时发现≥1.5×ULN升高并启动免疫抑制治疗。
  • ALT升高患者使用泼尼松60 mg/d治疗2周,ALT恢复基线后逐步减量。
  • 长期每3-6个月监测ALT,每6个月腹部超声,每年瞬时弹性成像评估。
  • 肝脂肪变性或其他肝病患者使用基因治疗前应高度个体化考虑肝损伤风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adeno-associated virus-based gene therapy (valoctocogene roxaparvovec) is an attractive treatment for hemophilia A. Careful clinical management is required to minimize the risk of hepatotoxicity, including assessment of baseline liver condition to determine treatment eligibility and monitoring liver function after gene therapy. This article describes recommendations (developed by a group of hemophilia experts) on hepatic function monitoring before and after gene therapy. To prevent harmful liver-related effects, gene therapy is contraindicated in patients with uncontrolled liver infections, autoimmune hepatitis, liver stiffness ≥8 kPa, or cirrhosis. Before using gene therapy in patients with liver steatosis or other liver disorders, the risk of liver damage should be considered using a highly individualized approach. Treatment is not recommended in patients with abnormal liver enzymes, including alanine aminotransferase (ALT) at any level above the upper limit of normal (ULN). Therefore, pretreatment assessment of liver health should include laboratory tests, abdominal ultrasound, and liver stiffness measurements by transient elastography (TE). In the first year after therapy, ALT levels should be monitored 1 to 2 times per week to detect elevations ≥1.5× ULN, which may require immunosuppressant therapy. Patients with ALT elevation should receive prednisone 60 mg/d for 2 weeks, followed by stepwise tapering when ALT returns to baseline. ALT monitoring should continue long term (every 3-6 months), along with abdominal ultrasound (every 6 months) and TE (yearly) evaluations. When patients with good liver health are selected for treatment and closely monitored thereafter, ALT elevations can be promptly treated and are expected to resolve without long-term hepatic sequelae.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. La Mura V, Cardinale V, De Cristofaro R, et al. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice. Blood Adv. 2024. PMID: 39226466. doi:10.1182/bloodadvances.2024013750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。